Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune)
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Pandemic influenza vaccine (H5N1) (live attenuated, nasal)
- Made by
- AstraZeneca AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age. Pandemic influenza vaccine H5N1 AstraZeneca should be used in accordance with official guidance
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | AstraZeneca AB |
|---|---|
| Active substance | Pandemic influenza vaccine (H5N1) (live attenuated, nasal) |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J07BB03 · Antibiotics, antivirals and antifungals taken into the body |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2016-05-20 |
| Last updated by the regulator | 2026-05-08 |
| EMA product number | EMEA/H/C/003963 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).